Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm

Summary

A single center, open-label, single arm study in patients who have solid or micropapillary adenocarcinoma with pathologic stage I and primary tumor no more than 4 cm. Pembrolizumab 200 mg every 3 weeks

Timeline

Start

2018-10-08

Primary completion

2021-03-30

Completion

2021-11-30

Outcome

Met primary endpoint

paper the 3-year disease-free survival (DFS) was 83·2%, meeting the survival endpoint of >80%. PMID 40524802 ↗

Publications

• Kim J, Bang YH, Park S, Jung HA, Sun JM, Ahn JS, Ahn MJ, Jeon YJ, Lee J, Cho JH, Kim HK, Choi YS, Zo JI, Shim YM, Kang JH, Lee J, Choi YL, Han J, Hwang S, Lee HY, Lee SH. Adjuvant pembrolizumab therapy for completely resected stage I lung adenocarcinoma with micropapillary or solid histological subtypes: a single-center, single-arm, phase 2 trial. EClinicalMedicine. 2025 Jun 4;84:103282. doi: 10.1016/j.eclinm.2025.103282. eCollection 2025 Jun.

Drugs

Indications